Disclaimer: This image is entirely AI-generated and is a product of artificial intelligence. Any resemblance to actual persons, whether living or deceased, is purely coincidental and unintentional.
Uploaded 1 month ago
Duration: 0h 4m 41s
Dr Reddy's profit down 14% on low Lenalidomide US sales
Pharma major Dr Reddy's Laboratories (DRL) reported a 14 per cent year-on-year (Y-o-Y) drop in consolidated net profit to Rs 1,210 crore in the December quarter of FY 2025-26 (Q3FY26) on low sales of cancer drug Lenalidomide in the North American market.
The firm's revenue from operations grew to Rs 8,727 crore in Q3FY26, a 4.4 per cent Y-o-Y increase from Rs 8,357 crore recorded for the same quarter last year.
Uploaded by: Rediff Video Desk on Thu, 22 Jan 2026 13:24:06 +0530
Views: 32
Tags: DRL, Dr Reddy, Central Drugs Standard Control Organisation, India, FY26, Q3FY26, Lenalidomide US, Health Canada, North America, Erez Israeli, GV Prasad, Visakhapatnam, BSE, NON, API, CEO
© 2026